TRIB2 and prostate carcinoma: Based on our findings, it appears that TRIB2 induces lineage switching by developing stemness and NE characteristics, which supports enzalutamide-resistant prostate cancer cells in a way that they are no longer required to depend on AR-mediated signaling.